MedPath
HSA Approval

BETACYLIC OINTMENT

SIN15211P

BETACYLIC OINTMENT

BETACYLIC OINTMENT

April 12, 2017

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

Formulation Information

OINTMENT

**Dosage & Administration:** Apply a thin film to completely cover the affected area, twice daily, in the morning and at night. For some patients, adequate maintenance therapy may be achieved with less frequent application. To be applied topically.

TOPICAL

Medical Information

**Indication(s):** Relief of the inflammatory manifestations of hyperkeratotic and dry corticosteroid-responsive dermatoses eg., psoriasis, chronic atopic dermatitis, neurodermatitis (lichen simplex chronicus), lichen planus, eczema (including nummular eczema, hand eczema, eczematous dermatitis), dyshidrosis (pompholyx), seborrheic dermatitis of the scalp, ichthyosis vulgaris and other ichthyotic conditions.

**Contraindication(s):** Patients with a history of sensitivity reactions to any of the components of this product.

D07BC01

betamethasone and antiseptics

Manufacturer Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Y.S.P. Industries (M) Sdn. Bhd.

Active Ingredients

Salicylic Acid

30mg/g

Salicylic acid

Betamethasone Dipropionate 0.643mg/g eqv Betamethasone

0.5mg/g

Betamethasone

Documents

Package Inserts

Betacyclic Ointment PI.pdf

Approved: April 20, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BETACYLIC OINTMENT - HSA Approval | MedPath